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Though at present there is no evidence-based algorithm for the treatment of 
primary Sjogren’s syndrome, it is generally accepted that glucocorticosteroid (GS) therapy 
must be introduced in cases with severe systemic manifestations. As the side-effects o f the 
GSs are well known, it would be useful to know in advance how the patients will respond 
to this type of treatment. For this reason we measured the in vitro steroid sensitivity of 29 
SS patients using inhibition of antibody dependent cellular cytotoxicity (ADCC) test by 
méthylprednisolone compared to that of 28 controls. SS patients proved to be significantly 
less sensitive to GSs than controls (inhibition of ADCC reaction: 42.4 vs 53.1%; p < 0.01). 
This was especially true in SS patients with anti-SSA and/or SSB autoantibody positivity 
and with HLA-DR2 and/or -DR3 alleles. Comparing the results of the in vitro GS 
sensitivity and the clinical effectiveness of the previously applied corticosteroid therapy it 
seems that steroid inhibition of ADCC reaction has a predictive value in determination of in 
vivo sensitivity to GSs. However, in patients with decreased in vitro GS sensitivity a more 
expressed in vivo steroid sensitivity cannot be excluded.
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Sjogren’s syndrome (SS) is one of the systemic inflammatory autoimmune 
diseases characterized by lymphocytic infiltration of exocrine glands, first of all the 
salivary and lacrimal ones. This results in xerostomia and xerophthalmia, which are the 
obligatory symptoms of the disease. The sicca symptoms can be present alone (primary
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SS), but can join other well-defined autoimmune connective tissue diseases (e.g. 
Rheumatoid arthritis, Systemic lupus erythematosus, etc.). This latter form is called 
secondary SS. In primary SS, beside the local symptoms, systemic manifestations 
(articular, lung, vascular, etc.) can also occur.
In SS patients, focal lymphoid infiltrates (predominantly CD4+ T-cells) are 
present in the lacrimal and salivary glands. Another important feature is the expression 
of HLA-DR antigens on the glandular epithelial cells [1]. Clinically, primary SS is 
characterized by hyperactivity of В cells which is manifested in polyclonal 
hypergammaglobulinaemia, and overproduction of different autoantibodies such as 
rheumatoid factor, anti-SSA/Ro and anti-SSB/La antibodies. The latter two antibodies 
are the most characteristic of the disease, and these are directed against small 
ribonucleoprotein antigens. SS is a multifactorial disease, and in its pathogenesis not 
only the immunological changes, but also genetic predisposition and environmental 
factors, such as viruses, are involved [2, 3].
Despite progress in understanding the pathogenesis of SS, at present there is no 
therapeutical modality that is effective towards the overall disease. For the treatment of 
dry mouth and eyes, the exocrine substitution and drugs, which can increase the 
lacrimal and salivary output, are the most important means of alleviating the sicca 
symptoms [4]. In cases with severe, sometimes life-threatening internal (kidney, lung, 
vascular, etc.) manifestations, GSs are generally used [5]. Taking into account the well- 
known short and long-term side-effects of steroid therapy, it would be essential to 
know in advance, whether a patient will or will not respond to GSs. For this reason we 
measured antibody-dependent cellular cytotoxicity (ADCC) reaction and in vitro 
méthylprednisolone inhibition of this reaction in patients with SS by methods described 
by Petri et al. [6, 7]. We wanted to know whether these in vitro examinations may help 
to determine the in vivo steroid sensitivity of SS patients if GS therapy is required. 
Another question was if HLA class II genotype, autoantibody positivity and clinical 
manifestations had any influence on GS sensitivity.
Patients and methods
ADCC activity and in vitro méthylprednisolone inhibition of the reaction were 
determined in 29 patients with primary Sjogren’s syndrome and in 28 age and sex- 
matched healthy blood donors as controls. All SS patients met the European Diagnostic 
Criteria (1993) [8].
Of the 29 patients all but one were female. The mean age of patients was 55 
years (range: 32-74 years) and the mean duration of the symptoms was 10.3 years 
(range: 1-20 years).
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In the ADCC reaction fresh, human “0” Rh (D) positive red blood cells were 
used as target cells. Human anti-D serum was adsorbed onto the cells [9] labelled with 
51Cr/Na2 5lCr0 4 ; 7-8 Gbq/mg Cr, Amersham. The effector lymphocytes were isolated 
on Ficoll Uromiro gradient after treatment of the whole blood with colloidal iron 
powder (GAF, USA). The effector/target cell ratio was adjusted to 10:1. 
Méthylprednisolone was added to the culture medium for a final concentration of 10 
pg/ml. The spontaneous activity was given by the count rates for cultures without anti- 
D antibody. The total activity was calculated as the radioactivity of labelled red blood 
cells lysed in distilled water. The cells were incubated at 37 °C in a 5% C 02 thermostat 
for 18 hours. The cytotoxicity and steroid inhibition were calculated by the next 
formulas:
test supernatant cpm -  spontaneous cpm
cytotoxicity % =---------------------------------------------------X 100
incorporated total activity cpm
ADCC with steroid (%)
steroid inhibition (%) = ---------------------------------- x 100
ADCC without steroid (%)
Grade of sensitivity to GSs was given as a percentage of the inhibition of the 
ADCC reaction due to the steroid. Steroid sensitivity was defined when inhibition of 
basic ADCC was >30% [6, 7].
Examination o f HLA status and autoantibody profile — statistical analysis
HLA II class antigenes, DRB1, DQA1 and DQB1 alleles were investigated in 
28 of the 29 SS patients. Genomic DNA was extracted by a standard phenol- 
chloroform-proteinase-K method [10]. Polymerase chain reaction (PCR) was carried 
out: 1. for DRB1 using Amplicor TM PCR Diagnostics KIT (Roche Diagnostics 
Systems), 2. for DQA1 using Ota’s PCR-RFLP method [11], 3. for DQB1 using 
Mercier’s PCR-RFLP method [12]. After polyacrylamide gel (12%) electrophoresis the 
alleles were determined by comparison of estimated fragment size with the predicted 
size.
Anti-SSA and anti-SSB autoantibody positivity was determined by enzyme- 
linked immunosorbent assay (Epignost, Leonding/Linz, Austria).
Statistical analysis was made by Dunnett-2-sided /-test, and Spearman’s 
correlation coefficients were calculated as well.
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Table I
Main clinical manifestations and laboratory variables in patients 
with primary Sjögren ’s syndrome (n=29)
Manifestations and laboratory changes Occurrence in frequency (%)
Parotid enlargement 10/29 (35%)
Articular 29/29 (100%)
Renal 4/29 (14%)
V ascular Raynaud 13/29 (45%)
Purpura 5/29 (17%)
Vasculitis 2/29 (7%)
Upper airway 27/29 (93%)
Lower airway 10/29 (35%)
Hepatomegaly 23/29 (79%)
Splenomegaly 7/29 (24%)
Lymphadenopathy 12/29 (41%)
Anaemia 14/29 (48%)
Leukopenia 15/29 (52%)
Hypergammaglobulinemia 15/29 (52%)
Antibody positivity
Antinuclear 20/29 (69%)
IgM Rheumatoid factor23/29 (79%)
Anti-SSA 19/29 (66%)
Anti-SSB 12/29 (41%)
Both Anti-SSA+SSB positive 11/29 (38%)
Both anti-SSA+SSB negative 9/29 (32%)
Results
The clinical manifestations and laboratory changes are summarized in Table I. 
Articular involvement (arthritis and arthralgia) occurred in all patients, followed by 
involvement of the upper airways (93%), anaemia and/or leukopenia (66%), Raynaud’s 
phenomenon (45%), parotid enlargement (35%), lower airway disease (35%), purpura 
(17%), kidney involvement (14%). Examining the autoantibody profile of the patients, 
IgM rheumatoid factor positivity occurred in 79%, whereas ANA-positivity and anti- 
SSA and/or anti-SSB was detected in 69% of the patients.
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Analyzing the results of ADCC reaction, there was a tendency for elevated 
ADCC reaction in SS patients (48.3 ± 15.7%), but the difference did not reach the level 
of significance comparing to that of controls (41.4 ± 14. 1%).
In contrast, the in vitro GS inhibition of the ADCC reaction was significantly 
lower (p < 0.01) in SS patients (42.4 ± 15.8%) than that in controls (53.1 ± 13.1%). The 
range of steroid inhibition varied between 39.9% and 66.2% in the healthy blood 
donors’ group and between 0 and 74% in SS patients. Twenty-three of 29 patients 
(79.3%) proved to be méthylprednisolone sensitive, whereas 6 patients (20.7%) showed 
a decreased sensitivity to GSs. This rate of sensitivity did not differ from that of the 
controls. We analyzed the results of in vitro méthylprednisolone inhibition of ADCC in 
SS patients on the basis of antibody profile and HLA status. The results are shown in 
Table II and III. The sensitivity to GSs decreased significantly in patients with anti- 
SSA and/or anti-SSB antibody positivity as compared to the controls. The difference 
proved also to be significant between the results of anti-SSB negative SS patients and 
controls. However, there were not any significant differences when the results of SS 
patients were compared with or without antibody positivity (Table II).
Table II
Steroid inhibition of ADCC reaction in primary Sjögren ’s syndrome (SS) patients (n=29) 
with or without anti-SSA and/or SSB antibody positivity comparing to controls (n=28)
Degree of inhibition (%)
Controls:
All SS patients
SS patients with 
anti-SSA+ (n=19) 
anti-SSA- (n-10) 
anti-SSB+ (n= 12) 
anti-SSB- (n=17) 
anti-SSA and SSB+ (n=l 1) 
anti-SSA and SSB- (n=9)
53. I±13.1 
42.4+15.8’ p<0.01
39.6+16.4’ p<0.005
47.7+16.0 NS
40.1+16.6* p<0.05
43.9+15.5’ p<0.05
39.6+17.3’ p<0.02
47.9+14.7 NS
+: patients with antibody positivity 
patients with antibody negativity
statistically significant differences as compared to controls 
NS: not significant
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Table III
Steroid inhibition o f ADCC reaction in Sjögren 's syndrome (SS) patients (n=28‘) 
with or without HLA DR2 and/or DR3 positivity as comparing to controls (n=28)
Degree of inhibition (%)
Controls: 53.1 ±13.16
All SS patients 42.4±15.8*
SS patients with HLA phenotype of
DR2 positivity (n=15) 37.9+20.8’ p<0.005
DR2 negativity (n=13) 45.8+10.6 NS
DR3 positivity (n=16) 40.3+15.6’ p<0.005
DR3 negativity (n=12) 44.7+17.0 NS
DR2 and DR3 positivity (n=6) 36.6+15.4*’ p<0.005
DR2 and DR3 negativity (n=5) 52.6+16.2 NS
significant difference as compared to controls and to DR2 and DR3 negative patients 
HLA phenotyping was carried out in 28 of the 29 SS patients 
’: significant difference as compared to controls 
NS: not significant
In HLA-DR2 and/or -DR3 positive patients the GS sensitivity was significantly 
lower than in controls. Though the steroid sensitivity was lower in SS patients with 
DR2 or DR3 positivity than in DR2 or DR3 negative patients, the differences were not 
statistically significant. In contrast, in cases with DR2/3 heterozygosity the difference 
proved to be statistically significant not only in comparison to controls, but also to SS 
patients carrying neither DR2 nor DR3.
Moreover we also evaluated the influence of combinations of both HLA 
haplotype (DR2, DR3), anti-SSA and SSB antibody positivity on the values of in vitro 
GS sensitivity (Table IV). We observed a tendency that SS patients with at least one of 
these alleles plus one of these autoantibodies exhibited lower sensitivity to 
méthylprednisolone than SS patients who possessed none or only one of the above- 
mentioned immunological and genetic markers. However, the difference proved to be 
significant only between DR2 plus anti-SSA positive and DR2 plus anti-SSA negative 
subgroups (p < 0.05).
Eight of 29 SS patients needed GS therapy because of systemic manifestations 
during the course of the disease. Six of the 8 steroid treated patients proved to be GS 
sensitive according to the in vitro examinations. This was in concordance with the 
clinical improvement after the administration of GSs. In contrast, 2 of the 8 steroid
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treated patients showed a decreased méthylprednisolone sensitivity on the basis of the 
ADCC inhibition. When they had to be treated with high dose of GS due to severe liver 
and lung involvements, they responded, however, well to this therapy.
Table IV
Steroid inhibition o f ADCC reaction in Sjögren 's syndrome (SS) patients (n=28‘) concerning both 
autoantibody and HI A status and in controls (n=28)
Degree of inhibition (%)
SS patients DR2+ DR2- DR3+ DR3-
Anti-SSA+ n=7 n—11 n=!2 n=6
32.1±22.2%’ 43.5±10.7% 37.6±I6.8% 42.2±17.6%
Anti-SSA- n=6 n=4 n=4 n=6
44.7±16.6% 52.3±8.4%’ 48.5±7.7% 47.2±17.6%
Anti-SSB+ n=3 n=8 n=9 n=2
34.7±31.6% 38.7±I0.7% 36.9±18.0% 51.0±7.7%
Anti-SSB- n=10 n=7 n=7 n=10
38 9±17.6% 51. I±8.5% 44.7± 11.7% 43.4±I8.3%
Anti-SSA+,SSB+ n=4 n=7 n=8 n=2
34.7±31.6% 40.6±l 1.3% 35.7±I8.9% 51.0±7.1%
Anti-SSA-,SSB- n=6 n=3 n=3 n=6
44.7±16.6% 54.3±9.0% 49.3±9.2% 47.2±17.6%
Controls (n=28) 53.1±13.2
AI! SS patients (n=28) 42.4±15.8
+: positivity 
negativity
*: HLA phenotyping was carried out in 28 of the 29 SS patients 
significant difference between the two subgroups
Discussion
As the ethiology of SS is unknown, a causal treatment is not available at 
present. Since there are considerable evidences for its immunological background, 
therefore immune-regulating drugs may be of therapeutic value. In spite of this fact, 
there is no evidence-based algorithm for the treatment. While the severe extraglandular 
manifestations (e.g. lung, kidney, etc.) can be decreased by administration of
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immunosuppressive treatment, local symptoms may fundamentally not be altered by 
this type of therapy [13].
Among the immunoregulatory modalities the GSs are used most frequently. For 
this reason it would be desirable to know in advance the therapeutic response to this 
type of drugs in patients with SS. This fact made us to investigate the ADCC reaction 
and in vitro méthylprednisolone inhibition of this reaction in our SS patients.
The role of RNP, Sm and SSA-specific antisera from patients with lupus 
erythematosus in inducing ADCC of target cells coated with nonhistone nuclear 
antigens was investigated by Norris et al. [14]. In SLE patients with high titer anti-RNP 
sera, a significantly increased ADCC was seen using monocytes, T-lymphocytes, and 
low-density lymphocyte effector. Using monocyte effectors, a significantly increased 
ADCC reaction was detected in patients with anti-RNP, anti-Sm, and anti-SSA 
autoantibodies. In contrast, neutrophils as effectors were ineffective in any tested 
nuclear antigen-antibody system.
Petri et al. [7] published a significant correlation between the clinical effect of 
prednisolone treatment, i.e. the prednisolone sensitivity, and the degree of GS 
sensitivity based on the percentage of ADCC inhibition in children with nephrotic 
syndrome.
Since mainly the IgG Fc-receptor bearing lymphocytes take part in the ADCC 
reaction, it is conceivable that the differences in GS sensitivity may be correlated with 
a shift in the proportion of different T-lymphocyte subpopulations. Crabtree et al. [15] 
presented considerable evidence that GSs inhibit T-cell proliferation by blocking of 
production of T-cell Growth Factor. Parillo and Fauci [16] found that GSs suppressed 
NK-cell activity in humans.
Anti-SSA autoantibodies have been shown to increase ADCC in vitro [14]. As a 
decreased GS sensitivity was observed in patients with anti-SSA and/or anti-SSB 
antibody positivity, it is conceivable that at certain genetic background these 
autoantibodies can influence the GS sensitivity, however, the exact mechanism in vivo 
is unknown. In the literature, only the beneficial effect of corticosteroids on circulating 
anti-ds-DNA titre has been proven [17].
Méthylprednisolone inhibition of the ADCC reaction was significantly 
decreased in pediatric autoimmune patients suffering from juvenile chronic arthritis or 
idiopathic thrombocytopenia [ 18].
Our working group [19] used the test of ADCC to investigate the in vitro GS 
sensitivity in patients with chronic uremia and in patients who underwent renal 
transplantation. While a positive correlation was detected between the HLA-DR6 
positivity and steroid sensitivity, a negative association was found in HLA-B8 carriers 
with the steroid sensitivity.
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In our SS patients, the effector peripheral lymphocytes demonstrated an 
increased ADCC reaction on the target red blood cells compared to those of controls, 
however, this was only a tendency. In SS patients and controls the rate of in vitro 
steroid sensitivity/resistance did not differ significantly, using 30% inhibition of ADCC 
reaction as a borderline. In contrast, the average GS inhibition showed a significant 
decrease in SS patients as compared to controls. This difference was more expressed in 
SS patients with HLA-DR2 or -DR3 haplotype than in patients not having these 
haplotypes. When these two alleles occurred together -  in cases of DR2/DR3 
heterozygotes -  the decrease of GS sensitivity was significant comparing not only to 
controls, but to SS patients without these two alleles.
We observed a similar correlation between the grade of sensitivity to GSs and 
anti-SSA and SSB autoantibody positivity. Our results suggest that anti-SSA antibody 
positivity has a greater impact on GS sensitivity.
Furthermore the tendency of being less sensitive to GSs was more expressed in 
any cases when both type of predisposing factors (genetic and immunological) 
occurred together. This is especially true for joint occurrence of HLA-DR2 and anti- 
SSA positivity. Comparing the results of the in vitro steroid sensitivity and the clinical 
effectiveness of the previously applied GS therapy, it seems that in vitro 
méthylprednisolone inhibition of ADCC reaction has a predictive value in 
determination of in vivo steroid sensitivity. However, in patients who exhibited a 
greatly decreased in vitro GS sensitivity, the in vivo steroid sensitivity cannot be 
excluded. For this reason, in severe cases with life-threatening manifestations GSs 
remain the main factors of therapy [20].
We conclude that sensitivity to GSs in patients with SS is influenced by both 
genetic haplotype and anti-SSA/anti-SSB seropositivity. Co-existence of these two 
factors may cause a decreased sensitivity to GSs. In vitro ADCC steroid inhibition test 
of the peripheral lymphocytes, coupled with the analysis of HLA class II allele 
polymorphism and autoantibody profile, was found to be a useful method for the 
detection of the grade of GS sensitivity in SS. This method may have a predictive value 
for making a decision of introducing of chronic GS therapy in other systemic 
autoimmune diseases, as well.
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